急性ST段抬高型心肌梗死的规范化溶栓治疗和溶栓剂选择

Standardized thrombolytic therapy and thrombolytic agent selection for acute ST segment elevation myocardial infarction

急性心肌梗死是致死率最高的心血管疾病之一,及时优化再灌注治疗以及第一时间开通血管,可以最大限度的挽救心肌。静脉溶栓治疗是重要的再灌注治疗策略,而静脉溶栓的成功率以及安全性与溶栓剂的选择密切相关。近年研发的特异性溶栓剂的广泛使用,可以提升救治效率,令患者获益最大化。本文就不同溶栓剂的临床价值以及目前的研究进展进行综述。

Acute myocardial infarction is one of the most deadly cardiovascular diseases. Early reperfusion can restore the blood flow at the first time,and maximize the rescue of the ischemic myocardium. Intravenous thrombolysis is a significant reperfusion method. Efficacy and safety of thrombolysis are closely related to the selection of thrombolytic agents. The wide use of new specific thrombolytic agents developed in recent years can improve the efficacy of treatment and maximize the benefit of patients. In this article,the clinical values of different thrombolytic agents and the current research progress were reviewed.